<DOC>
	<DOCNO>NCT02030054</DOCNO>
	<brief_summary>Statin interference suggest among mechanisms reduction antiplatelet effect clopidogrel . The purpose study evaluate pharmacodynamic effect rosuvastatin atorvastatin platelet reactivity patient coronary artery disease undergone double antiplatelet therapy new P2Y12 inhibitor . This single-center , prospective , randomize , crossover study conduct Department Heart Great Vessels `` Attilio Reale '' , Sapienza University , Rome , Italy . All consecutive patient undergone PTCA institution period July 2013 December 2013 eligible enrol . Patients offer participate trial time 1-month post-angioplasty follow-up visit.patients receive dual antiplatelet therapy ( prasugrel 10 mg brilique 90 mg x 2 plus aspirin 100 mg ) percutaneous coronary intervention . Patients randomly assign rosuvastatin ( 20 mg day ) atorvastatin ( 40 mg day ) 30 day . After 1-week wash-out period avoid carryover effect , cross-over perform , patient switch drug continue 30 day . Platelet function evaluate use validated method : VerifyNow System ( Accumetrics Inc. , San Diego , CA ) , point-of-care turbidimetry-based optical detection system measure platelet-induced aggregation . Platelet function measure VerifyNow P2Y12 test baseline 30 day rosuvastatin atorvastatin administration . Platelet reactivity express P2Y12 reaction unit ( PRU ) . PRU value &gt; 208 suggestive high platelet reactivity .</brief_summary>
	<brief_title>Pharmacodynamic Comparison Rosuvastatin Versus Atorvastatin Platelet Reactivity Patients With Coronary Artery Disease Dual Antiplatelet Therapy With New P2Y12 Inhibitors ( Trial gRANADa )</brief_title>
	<detailed_description>Statin interference suggest among mechanisms reduction antiplatelet effect clopidogrel . The purpose study evaluate pharmacodynamic effect rosuvastatin atorvastatin platelet reactivity patient coronary artery disease undergone double antiplatelet therapy new P2Y12 inhibitor . This single-center , prospective , randomize , crossover study conduct Department Heart Great Vessels `` Attilio Reale '' , Sapienza University , Rome , Italy .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Angiographicallyproven coronary artery disease ; 2 . Able understand willing sign inform CF ; 3 . Stable clinical condition ; 4. treatment dual antiplatelet therapy ( P2Y12 inhibitor ) ; 1 . Other drug medication affect CYP mediate drug metabolism ; 2 . Allergy adverse reaction administer drug ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>